Novartis Q2 Results Beat Expectations
Novartis shares rose approximately 5% in early Tuesday trading following better-than-expected second-quarter results on both revenue and earnings per share (EPS). The Swiss pharmaceutical company reaffirmed its guidance for the year, with full-year revenue consensus at $58.05 billion and non-GAAP EPS of $8.68.
Tickers: $NVS
Topics: Financial Performance Pharmaceuticals